Evidence map›Paper›PMID 33319845›Full record

ArticleScientific reports2020

Possible proteomic biomarkers for the detection of pancreatic cancer in oral fluids.

O Deutsch, Y Haviv, G Krief, N Keshet, R Westreich, S M Stemmer, B Zaks, S P Navat, R Yanko, O Lahav and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review: Detection of Cancer Biomarkers from a Clinical Perspective.International journal of molecular sciences · 2025
    Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

O DeutschInstitute of Dental Sciences, Faculty of Dental Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Y HavivSalivary Gland Clinic and Saliva Diagnostic Laboratory, Department of Oral Medicine, Sedation and Maxillofacial Radiology, Sjogren's Syndrome Center, Hadassah Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel.
G KriefInstitute of Dental Sciences, Faculty of Dental Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
N KeshetSalivary Gland Clinic and Saliva Diagnostic Laboratory, Department of Oral Medicine, Sedation and Maxillofacial Radiology, Sjogren's Syndrome Center, Hadassah Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel.
R WestreichDepartment of Internal Medicine B, Soroka Medical Center, Beer-Sheva, Israel.
S M StemmerRabin Medical Center, Davidoff Center, Petach Tiqwa, Affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
B ZaksInstitute of Dental Sciences, Faculty of Dental Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
S P NavatInstitute of Dental Sciences, Faculty of Dental Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
R YankoSalivary Gland Clinic and Saliva Diagnostic Laboratory, Department of Oral Medicine, Sedation and Maxillofacial Radiology, Sjogren's Syndrome Center, Hadassah Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel.
O LahavInstitute of Dental Sciences, Faculty of Dental Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
D J AframianSalivary Gland Clinic and Saliva Diagnostic Laboratory, Department of Oral Medicine, Sedation and Maxillofacial Radiology, Sjogren's Syndrome Center, Hadassah Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel.
A PalmonInstitute of Dental Sciences, Faculty of Dental Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel. yaronha@hadassah.org.il.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 80% mortality rate of pancreatic-cancer (PC) makes early diagnosis a challenge. Oral fluids (OF) may be considered the ultimate body fluid for non-invasive examinations. We have developed techniques to improve visualization of minor OF proteins thereby overcoming major barriers to using OF as a diagnostic fluid. The aim of this study was to establish a short discriminative panel of OF biomarkers for the detection of PC. Unstimulated OF were collected from PC patients and controls (n = 30). High-abundance-proteins were depleted and the remaining proteins were analyzed by two-dimensional-gel-electrophoresis and quantitative dimethylation-liquid-chromatography-tandem mass-spectrometry. Label-free quantitative-mass-spectrometry analysis (qMS) was performed on 20 individual samples (n = 20). More than 100 biomarker candidates were identified in OF samples, and 21 had a highly differential expression profile. qMS analysis yielded a ROC-plot AUC value of 0.91 with 90.0% sensitivity and specificity for a combination of five biomarker candidates. We found a combination of five biomarkers for PC. Most of these proteins are known to be related to PC or other gastric cancers, but have never been detected in OF. This study demonstrates the importance of novel OF depletion methodologies for increased protein visibility and highlights the clinical applicability of OF as a diagnostic fluid.

Indexed as

ProteomicsAgedBiomarkers, TumorCase-Control StudiesElectrophoresis, Gel, Two-DimensionalHumansMethylationMiddle AgedNeoplasm ProteinsPancreatic NeoplasmsSalivaBiomarkers, TumorNeoplasm Proteins

Identifiers

PMID33319845
PMCPMC7738525

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.